AI vs. doctors: who spots kidney danger from chemo first?
NCT ID NCT07114276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a machine learning model could predict kidney injury caused by platinum chemotherapy more accurately than doctors. Researchers followed 77 cancer patients receiving cisplatin or carboplatin, tracking their kidney function over time. The goal was to see if the computer model could better forecast acute kidney injury within 14 days or kidney disease within 89 days, compared to clinical judgment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- machine learning model
- What this could lead to
- If successful, this could help doctors identify patients at high risk for kidney damage from platinum chemotherapy, allowing for earlier protective measures.
- What could go wrong
- This is a small, completed study (77 patients) that only tests prediction accuracy, not whether using the model actually improves patient outcomes. The model may not work as well in other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Medical University Wan Fang Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Which emergency dialysis saves more lives? a new study investigates
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare